Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2026-05-16 @ 5:55 PM
Study NCT ID:
NCT01060904
Status:
COMPLETED
Last Update Posted:
2014-12-18
First Post:
2010-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
Sponsor:
Seagen Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SGN35-009
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |